Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapies for metabolic liver diseases, primarily nonalcoholic steatohepatitis (MASH). Its flagship product, Rezdiffra (resmetirom), is a liver-directed oral therapy targeting fibrosis and inflammation. The company aims to address high unmet medical needs, expand indications, and obtain regulatory approvals globally, leveraging proprietary technology and strategic collaborations.
This description was generated via AI from an annual report. Updated about 1 year ago.